Generic versions of semaglutide-based drugs like Wegovy and Ozempic are now available in Canada, with broader rollouts expected to reach countries covering 40% of the global population within the next year at prices as low as $15 per month. The U.S. market remains protected by Novo Nordisk's active patents, keeping branded drug prices in the hundreds of dollars monthly. This divergence is creating a two-speed global market for GLP-1 drugs — competitive and cheap abroad, monopolistic and expensive at home.
Novo Nordisk's premium pricing power — the engine behind its extraordinary revenue growth — is being tested internationally, which compresses its long-term earnings outlook outside the U.S. If patent cliffs accelerate or political pressure mounts to allow generics stateside, the stock faces a significant re-rating downward. Investors holding NVO directly or through health-focused ETFs should track the timeline of U.S. patent expiration closely.
Q2 2025: Watch for Novo Nordisk's next earnings call for updates on international revenue pressure. Mid-2025: Monitor FDA and U.S. congressional discussions on drug pricing reform. 2026–2027: Key U.S. patent expiration window for semaglutide formulations begins.
Full analysis · Subscribers
The deep dive (bull case, bear case, and the data point that decides which side wins), the cause-and-effect chain behind the move, plain-English explainers for every block.
Aggregated reads dozens of sources in five languages and turns the day into plain-English cards like this one.
Educational analysis of public information, not investment advice. Report an error · Corrections policy
← Today's brief